Drug intelligence / Profile preview

ferrous sulfate + levothyroxine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

This represents a clinically significant drug interaction rather than an intentional combination therapy. Ferrous sulfate is an iron supplement used to treat iron deficiency anemia, while levothyroxine is a synthetic thyroid hormone used to treat hypothyroidism. When taken simultaneously, ferrous sulfate forms insoluble complexes with levothyroxine in the gastrointestinal tract, reducing levothyroxine's bioavailability by up to 40-50%. This interaction can lead to inadequate thyroid hormone replacement, elevated TSH levels, and recurrence of hypothyroid symptoms in previously stable patients.

Targets

THR (Thyroid hormone receptor)

Beyond the preview

Go deeper on ferrous sulfate + levothyroxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ferrous sulfate + levothyroxine.

Explore the full profile